Skip to main content

Prospective Observational Post-Marketing Study of Tafluprost for Glaucoma and Ocular Hypertension: Effectiveness and Treatment Persistence

Abstract

Introduction

The aim of this study was to investigate the long-term intraocular pressure (IOP)-lowering effect and safety of tafluprost, a prostaglandin analogue, in actual clinical practice and to determine persistency of tafluprost as an indicator of its benefit–risk balance.

Methods

This was a large-scale, post-marketing, multicenter, non-interventional, open-label, long-term study. Patients with glaucoma or ocular hypertension who initiated tafluprost treatment were registered and prospectively observed over a 2-year period in the real-world setting in Japan. Long-term IOP and safety data were collected.

Results

Of the 4502 patients registered from 553 medical institutions, 4265 patients were analyzed. The majority of patients had normal-tension glaucoma (44.4%) and primary open-angle glaucoma (37.8%), and patients with ocular hypertension constituted 7.0%. Treatment patterns with tafluprost during the study period were as follows: naïve monotherapy (48.1%), switching monotherapy (18.4%), and concomitant therapy (33.5%). In all patients analyzed, mean IOP was significantly reduced from 18.6 ± 5.9 mmHg (month 0) to 15 mmHg or below throughout the 2-year observation period after initiation of tafluprost. Significant IOP-lowering effects were shown in various treatment patterns and disease types. Adverse reactions were observed in 795 patients (18.64%). Major adverse reactions included eyelid pigmentation, ocular hyperemia, eyelash changes, eyelid hypertrichosis, and iris hyperpigmentation. Kaplan–Meier curves showed that 84.6% and 76.1% of patients were persistent on tafluprost for 1 and 2 years, respectively, when discontinuation due to insufficient efficacy or adverse events was defined as a treatment failure event. Furthermore, among treatment-naïve patients (n = 2304), the persistency rates on tafluprost monotherapy were 77.0% for 1 year and 67.0% for 2 years.

Conclusion

Tafluprost showed significant long-term IOP-lowering effects regardless of treatment patterns or diagnosis, with minimum safety concerns in the actual clinical practice. The observed treatment persistence suggests that tafluprost can be used long term owing to its benefit–risk profile.

Funding

Santen Pharmaceutical Co., Ltd., Osaka, Japan.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

References

  1. 1.

    European Glaucoma Society. Terminology and guidelines for glaucoma. 3rd ed. Savona: DOGMA; 2008.

    Google Scholar 

  2. 2.

    Kuwayama Y, Komemushi S. Phase III confirmatory study of 0.0015% DE-085 (tafluprost) ophthalmic solution as compared to 0.005% latanoprost ophthalmic solution in patients with open-angle glaucoma or ocular hypertension. Atarashii Ganka (J Eye). 2008;25:1595–602.

    Google Scholar 

  3. 3.

    Kuwayama Y, Komemushi S, Tafluprost Multi-center Study Group. Intraocular pressure-lowering effect of 0.0015% tafluprost as compared to placebo in patients with normal-tension glaucoma: randomized, double-blind, multicenter, phase III study. Nippon Ganka Gakkai Zasshi. 2010;114:436–43.

    PubMed  Google Scholar 

  4. 4.

    Kuwayama Y, Nomura A. Prospective observational post-marketing study of tafluprost for glaucoma and ocular hypertension: short-term efficacy and safety. Adv Ther. 2014;31:461–71.

    CAS  Article  PubMed  Google Scholar 

  5. 5.

    Iwase A, Suzuki Y, Araie M, et al. The prevalence of primary open-angle glaucoma in Japanese: the Tajimi Study. Ophthalmology. 2004;111:1641–8.

    PubMed  Google Scholar 

  6. 6.

    Inoue K, Setogawa A, Tomita G. Nonresponders to prostaglandin analogs among normal-tension glaucoma patients. J Ocul Pharmacol Ther. 2016;32:90–6.

    CAS  Article  PubMed  Google Scholar 

  7. 7.

    Yoshino T, Fukuchi T, Togano T, Seki M, Ikegaki H, Abe H. Eyelid and eyelash changes due to prostaglandin analog therapy in unilateral treatment cases. Jpn J Ophthalmol. 2013;57:172–8.

    CAS  Article  PubMed  Google Scholar 

  8. 8.

    Zimmerman TJ, Hahn SR, Gelb L, Tan H, Kim EE. The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence. J Ocul Pharmacol Ther. 2009;25:145–52.

    CAS  Article  PubMed  Google Scholar 

  9. 9.

    Zhou Z, Althin R, Sforzolini BS, Dhawan R. Persistency and treatment failure in newly diagnosed open angle glaucoma patients in the United Kingdom. Br J Ophthalmol. 2004;88:1391–4.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  10. 10.

    Nordstrom BL, Friedman DS, Mozaffari E, Quigley HA, Walker AM. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol. 2005;140:598–606.

    Article  PubMed  Google Scholar 

  11. 11.

    Owen CG, Carey IM, de Wilde S, Whincup PH, Wormald R, Cook DG. Persistency with medical treatment for glaucoma and ocular hypertension in the United Kingdom: 1994–2005. Eye. 2009;23:1098–110.

    CAS  Article  PubMed  Google Scholar 

  12. 12.

    Rahman MQ, Abeysinghe SS, Kelly S, et al. Persistence of glaucoma medical therapy in the Glasgow Glaucoma Database. Br J Ophthalmol. 2011;95:966–70.

    CAS  Article  PubMed  Google Scholar 

  13. 13.

    Holló G, Thelen U, Teus MA, et al. Long-term outcomes of prostaglandin analog versus timolol maleate in ocular hypertensive or primary open-angle glaucoma patients in Europe. J Ocul Pharmacol Ther. 2011;27:493–8.

    Article  PubMed  Google Scholar 

  14. 14.

    Friström B, Uusitalo H. A randomized, 36-month, post-marketing efficacy and tolerability study in Sweden and Finland of latanoprost versus non-prostaglandin therapy in patients with glaucoma or ocular hypertension. Acta Ophthalmol. 2010;88:37–43.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

Sponsorship and article processing charges for this study were funded by Santen Pharmaceutical Co., Ltd., Osaka, Japan. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis. We wish to express our gratitude to the physicians at the medical institutions that cooperated in the study. English language editing and manuscript preparation for submission for this study were provided by Springer Healthcare Communications. This support was funded by Santen Pharmaceutical Co., Ltd.

Disclosures

Yasuaki Kuwayama is a consultant for Alcon Japan, Kowa Company, Ltd., Otsuka Pharmaceutical, Pfizer Japan, Santen Pharmaceutical, and Senju Pharmaceutical and has received speaker honoraria from Alcon Japan, Kowa Company, Ltd., Otsuka Pharmaceutical, Pfizer Japan, Santen Pharmaceutical, and Senju Pharmaceutical. Masako Hashimoto is an employee of Santen Pharmaceutical Co., Ltd. Reiko Kakegawa is an employee of Santen Pharmaceutical Co., Ltd. Akio Nomura is an employee of Santen Pharmaceutical Co., Ltd. Fumiki Shimada is an employee of Santen Pharmaceutical Co., Ltd.

Compliance with Ethics Guidelines

This mandatory observational study was conducted in accordance with the requirements of the Good Post-Marketing Study Practice (MHLW Ordinance No. 171; December 20, 2004), the regulatory authority in Japan. Because the study protocol was reviewed and approved by the regulatory authority in Japan prior to initiation, approval by the ethics review committees at each participating medical institution was not required. The Japanese regulatory authority does not require informed consent for post-marketing observational studies; therefore, this study did not obtain informed consent from patients.

Data Availability

The datasets during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Yasuaki Kuwayama.

Additional information

Enhanced content

To view enhanced content for this article go to http://www.medengine.com/Redeem/9D18F06072676AA6.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kuwayama, Y., Hashimoto, M., Kakegawa, R. et al. Prospective Observational Post-Marketing Study of Tafluprost for Glaucoma and Ocular Hypertension: Effectiveness and Treatment Persistence. Adv Ther 34, 1411–1425 (2017). https://doi.org/10.1007/s12325-017-0549-0

Download citation

Keywords

  • Adverse event
  • Glaucoma
  • Intraocular pressure
  • Observational post-marketing study
  • Ocular hypertension
  • Ophthalmology
  • Tafluprost
  • Treatment persistence